CHARLOTTESVILLE, Va., June 25 /PRNewswire/ -- Adenosine Therapeutics, LLC, announced today the appointment of Dr. Jonathan Sackier and Dr. Steven Tregay, two prominent members of the scientific and business communities, to its Board of Directors.
Dr. Jonathan Sackier brings over 25 years of healthcare experience to the Company. After training as a surgeon in the United Kingdom, he was recruited to the USA in the 1980's and was a leader in the development of laparoscopic surgery. As a Professor at George Washington University in Washington, DC, he founded, and funded, the Washington Institute of Surgical Endoscopy, a center for education, research and technological innovation. He is also a Visiting Professor at the University of Virginia with activities in basic and clinical research supported by multiple grants. His work has led to multiple publications and he has served many journals as an editor or reviewer.
Dr. Sackier has collaborated with the pharmaceutical and medical device industry and developed multiple technologies that have been licensed and brought to market with partners such as Valleylab, Pfizer, Karl Storz, Applied Medical and Pall. In the mid 1980's his team discovered and patented a line of amniotic stem cells and the resultant company, "Genethics," licensed the rights to a publicly traded British pharmaceutical company. He also helped develop the AESOP robotic device and the related company, Computer Motion, had a successful IPO in 1997. He has also been a consultant to many healthcare companies, has advised the investment banking and private equity community on seed, venture and mezzanine funding, as well as merger and acquisition and IPO activity.
Dr. Steven Tregay received his undergraduate degree in Chemistry from Davidson College and received his Ph.D. and M.S. in organic chemistry from Harvard University with Prof. David Evans. Dr. Tregay brings a range of experiences in both biotech and the multi-national pharmaceutical industries including roles in research, business development and venture capital investing. He is a Managing Director of the $200M Novartis Option Fund where he has led the fund's investment in Adenosine Therapeutics and Cequent Pharmaceuticals, where he also serves on the Board of Directors. Prior to joining the venture group, he was the Executive Director and Head of Strategic Alliances-Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research.
Dr. Tregay managed a team of ten who were responsible for identification, negotiation and management of collaborations for the Oncology and Ophthalmology disease areas and the Technology areas including Global Discovery Chemistry; Discovery Technologies; Molecular and Developmental Pathways; Mouse Models of Diseases; Genomic and Proteomics Sciences; Kinase, Protease, and GPRC platforms. Prior to joining Novartis, he had roles in business development at Array BioPharma and prior to Array, Steve worked as a medicinal chemist.
"We feel greatly honored to have both Jonathan and Steve on the Adenosine Board," said Robert Capon, CEO and co-founder of Adenosine Therapeutics, LLC. "They bring a wealth of scientific and business expertise to the Company."
About Adenosine Therapeutics
Adenosine Therapeutics is a world leader in the development of novel pharmaceutical products that target adenosine receptor subtypes. The company's most advanced product is Apadenoson, a highly selective A2A agonist, which is in Phase III clinical development for use as a stress agent during cardiac imaging. The Company is also developing drugs for the treatment of asthma, diabetes, Parkinson's disease, cancer, ophthalmic disease and inflammatory indications such as sepsis, heart attack, ischemia-reperfusion injury, sickle cell crisis, vascular injury, arthritis, spinal cord injury, COPD, and inflammatory bowel disease. For more information on Adenosine Therapeutics, please visit our web site at www.adenrx.com.
Adenosine Therapeutics, LLC